573675-29-3 Usage
General Description
7-Bromopyrido[3,2-d]pyrimidin-4(3H)-one is an organic compound with the molecular formula C8H5BrN4O. It is a heterocyclic compound containing a pyrido[3,2-d]pyrimidine ring system with a bromine substituent and a carbonyl group at the 4-position. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It has potential applications in the field of medicinal chemistry, particularly in the development of new drugs for the treatment of various diseases. Additionally, 7-Bromopyrido[3,2-d]pyrimidin-4(3H)-one may also have other industrial uses, such as in the production of specialty chemicals or as a reagent in organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 573675-29-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,3,6,7 and 5 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 573675-29:
(8*5)+(7*7)+(6*3)+(5*6)+(4*7)+(3*5)+(2*2)+(1*9)=193
193 % 10 = 3
So 573675-29-3 is a valid CAS Registry Number.
573675-29-3Relevant articles and documents
ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
-
Paragraph 0284; 0285, (2021/01/25)
The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.
CAPSAICIN RECEPTOR AGONISTS
-
Page/Page column 44, (2010/02/11)
Capsaicin receptor agonists are provided. Such compounds are ligands that may be used to modulate VRl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to capsaicin receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.